PipelineReview.com13 小时
Vaxxas and CEPI Advance US$4.8 million (AU$7.2 million) Program for Needle-Free ...
CAMBRIDGE, MA, USA & BRISBANE, Australia I2, 2025 I Vaxxas, a clinical-stage biotechnology company commercializing a novel high-density ...